Entresto

E584152

Entresto is a prescription heart failure medication that combines sacubitril and valsartan to reduce the risk of cardiovascular death and hospitalization.

Try in SPARQL Jump to: Statements Referenced by

Statements (46)

Predicate Object
instanceOf brand name medication
pharmaceutical drug
actsOn renin-angiotensin-aldosterone system
ATCCode C09DX04
blackBoxWarning fetal toxicity
containsSubstanceRole angiotensin II receptor blocker
neprilysin inhibitor
contraindication concomitant use with ACE inhibitors
history of angioedema related to ACE inhibitor or ARB therapy
pregnancy
developer Novartis NERFINISHED
drugClass ARNI
angiotensin receptor neprilysin inhibitor
effect reduces cardiovascular mortality in heart failure patients
reduces hospitalization for heart failure
hasActiveIngredient sacubitril
valsartan
hasComponentOfFixedDoseCombination sacubitril
valsartan
hasDosageForm film-coated tablet
indication chronic heart failure
heart failure with reduced ejection fraction
reduction of risk of cardiovascular death and hospitalization for heart failure
legalStatusEU prescription only medicine
legalStatusUS Rx-only
marketingAuthorizationHolder Novartis NERFINISHED
mechanismOfAction blocks angiotensin II type 1 receptors
inhibits neprilysin to increase natriuretic peptides
pregnancyCategory contraindicated in pregnancy
prescriptionStatus prescription only
regulatoryStatus EMA approved
FDA approved
requiresWashoutPeriodWith ACE inhibitors
routeOfAdministration oral
sideEffect cough
dizziness
hyperkalemia
hypotension
renal impairment
targetPopulation adult patients with chronic heart failure
therapeuticArea cardiology
heart failure management
warning impaired renal function
risk of angioedema
risk of hyperkalemia
risk of hypotension

Referenced by (1)

Full triples — surface form annotated when it differs from this entity's canonical label.

Novartis notableDrug Entresto